Basic Information
| LncRNA/CircRNA Name | LINC00852 |
| Synonyms | NA |
| Region | GRCh38_3:10284419-10285746 |
| Ensemble | ENSG00000231177 |
| Refseq | NR_026829 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | lung adenocarcinoma |
| ICD-0-3 | C34 |
| Methods | qPCR, Western blot, in vitro knockdown, etc. |
| Sample | primary lung adenocarcinoma, lung adenocarcinoma SM, Human lung adenocarcinoma cell lines A549 and SPCA-1 |
| Expression Pattern | differentially expressed |
| Function Description | LINC00852 and the mitogen-activated protein kinase (MAPK) pathway were found to be associated with SM. Moreover, the LINC00852 target S100A9 had a positive regulatory role in the progression, migration, invasion, and metastasis of lung adenocarcinoma cells, both in vitro and in vivo. Furthermore, S100A9 strongly activated the P38 and REK1/2 kinases, and slightly activated the phosphorylation of the JNK kinase in the MAPK pathway in A549 and SPCA-1 cells. |
| Pubmed ID | 30519313 |
| Year | 2018 |
| Title | LINC00852 Promotes Lung Adenocarcinoma Spinal Metastasis by Targeting S100A9 |
External Links
| Links for LINC00852 | GenBank HGNC NONCODE |
| Links for lung adenocarcinoma | OMIM COSMIC |